Watson Pharmaceuticals: 2024 Annual Results Forecast

SZSIJan 24 00:00 · Announcements

Chongqing Pharscin Pharmaceutical (002907.SZ): The net income for the year 2024 is expected to increase by 71.26%-147.71%.

Gelonghui, on January 23, announced that Chongqing Pharscin Pharmaceutical (002907.SZ) released its performance forecast for 2024. The net income attributable to the shareholders of the listed company is expected to be between 56 million yuan and 81 million yuan, representing an increase of 71.26%-147.71% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be between 40 million yuan and 57 million yuan, showing a rise of 92.88%-174.86% year-on-year; the basic EPS is expected to be between 0.1341 yuan/share and 0.1940 yuan/share. During the reporting period, the company's main business revenue...

Gelonghui FinanceJan 23 16:45

Express News | Chongqing Pharscin Pharmaceutical: The company has completed the domestic production pharmaceutical registration for three products.

BreakingsJan 10 16:20

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Express News | Chongqing Pharscin Pharmaceutical's Ganqiao Bingmei tablets have been approved for sale in Singapore, with the first batch of Pharmaceuticals shipped on December 13.

BreakingsDec 16, 2024 11:45

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24